Principal Scientist
Pfizer Inc
Groton
Mark Niosi, a distinguished scientist with over 23 years of expertise in drug metabolism and pharmacokinetics (~3 yr3 at Purdue Pharma, and +20 yrs at Pfizer). Studied Toxicology at Saint John’s University (Dr. Balkon) and graduate studies in Forensic Toxicology (Dr. Trombetta).
He has been deeply engaged in the drug discovery and development efforts for degraders at Pfizer, spanning from early concept to late-stage clinical aspects. He contributes to troubleshooting and profiling ADME properties and performing DDI risk assessments across a broad spectrum of projects; from small molecules and those beyond Ro5, with a pioneering focus on PROTACs.
He has been at the forefront of innovation, integrating new technologies like LC/MS platforms, ex vivo absorption techniques, GastroPlus PBPK modeling, ACD simulations, and inhouse insilico modeling - pushing the boundaries of pharmaceutical research.
Mark also serves as a lab head, and mentors our next generation of scientists, driving the development and optimization of enzymology in vitro and in vivo assays. As a recognized leader in the field, a frequent collaborator on scientific publications and has been invited to speak at various conferences. He is passionate to advance the field of pharmaceutical sciences, while fostering collaboration and nurturing the future of medicine.
Disclosure information not submitted.
Speaker Spotlight: Assessment of Permeability: Bridging Traditional and Novel Compounds in Discovery
Monday, October 21, 2024
9:30 AM – 10:30 AM MT